A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Reported by CNBC — Top News.
This story is developing. Read the full report from CNBC — Top News.
Original reporting
This brief was written with AI assistance from the reports listed above and checked against our editorial policy. Spotted an error? Request a correction.
